News headlines about Esperion Therapeutics (NASDAQ:ESPR) have trended positive on Sunday, according to Accern Sentiment. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Esperion Therapeutics earned a media sentiment score of 0.35 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 44.6971867648071 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Esperion Therapeutics (ESPR) opened at $74.92 on Friday. The company has a market capitalization of $1,930.00, a PE ratio of -10.92 and a beta of 2.64. Esperion Therapeutics has a 52 week low of $20.39 and a 52 week high of $82.18.
Several brokerages have recently weighed in on ESPR. BidaskClub downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Bank of America upgraded Esperion Therapeutics from a “neutral” rating to a “buy” rating and set a $76.00 target price for the company in a research note on Friday, January 5th. Needham & Company LLC upgraded Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and raised their target price for the company from $72.00 to $81.00 in a research note on Thursday, December 14th. Chardan Capital raised their target price on Esperion Therapeutics from $20.00 to $75.00 and gave the company a “neutral” rating in a research note on Wednesday, December 6th. Finally, UBS Group set a $88.00 target price on Esperion Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 17th. Six analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $77.23.
In related news, Director Nicole Vitullo sold 11,674 shares of Esperion Therapeutics stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $71.79, for a total value of $838,076.46. Following the completion of the transaction, the director now directly owns 3,177 shares in the company, valued at $228,076.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 32.50% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Positive Media Coverage Somewhat Unlikely to Affect Esperion Therapeutics (ESPR) Stock Price” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://ledgergazette.com/2018/02/18/positive-media-coverage-somewhat-unlikely-to-affect-esperion-therapeutics-espr-stock-price.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.